Although renal cell carcinoma (RCC) is more commonly found in adults older than 60 years, recent data show a rising rate of aggressive RCC among US adults aged 20 to 39 years. Cancer stage migration ...

Among modern cancer therapies, immune checkpoint inhibitors (ICI) are among the most successful treatment methods. These ...

Stage 3 RCC involves tumor growth beyond the kidney, affecting nearby tissues or lymph nodes, but not distant organs. Diagnosis includes imaging, biopsy, and molecular testing to guide treatment ...

Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called "myeloid mimicry" to hide from the immune system ...

The combination of PD-L1 and CTLA-4 inhibition improves disease-free survival after surgery in patients with primary renal cell carcinoma, a phase 3 trial finds. For patients with renal cell carcinoma ...

The combination of belzutifan and lenvatinib significantly improved PFS and ORR in advanced ccRCC patients post anti-PD-1/L1 therapy. A trend towards improved OS was observed, though not statistically ...

RAHWAY, N.J.,--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Renal cell carcinoma (RCC) patients with hypercalcemia (HC) have worse outcomes. HC often involves PTHrP, and the role of HIF-2 is incompletely understood. Leveraging RCC tumorgraft (TG) models of HC, ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...

ABSTRACT: The incidence of renal cell cancer has risen over the recent years, and with the use of new diagnostic imaging modalities, the detection rate has also increased. Clear cell carcinoma is the ...

Head-to-head trials directly comparing these combination regimens are lacking, and differences in study populations, end points, and follow-up durations inherently limit cross-trial comparisons.

KIM-1 is overexpressed in kidney tumors and detectable in circulation years before RCC diagnosis, aiding early detection and risk stratification. High KIM-1 levels are associated with worse metastasis ...